(Total Views: 95)
Posted On: 09/16/2024 4:55:34 PM
Post# of 113
NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports TNX-801 Aligns with WHO Preferred TPP for Mpox Vaccines
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates, is reporting that the World Health Organization’s (“WHO”) preferred target product profile (“TPP”) aligns with the characteristics of its proprietary TNX-801 (horsepox, live virus) vaccine; Tonix is developing the vaccine for mpox (formerly known as monkeypox). WHO released the TPP at the Mpox Research and Innovation Scientific Conference, which was held Aug. 29–30, 2024,
According to the announcement, key elements of the WHO draft TPP include single-dose, durable protection, administration without special equipment and stability at ambient temperature.
“The characteristics of TNX-801 align with the draft TPP released at the WHO-sponsored Mpox Research and Innovation Scientific Conference,” said Tonix Pharmaceuticals CEO Seth Lederman, MD, in the press release. “The recent WHO declaration of a Public Health Emergency of International Concern (‘PHEIC’) underscores the urgent need for new vaccines to control this outbreak and save lives. We have been motivated to develop TNX-801 because single-dose vaccines simplify logistics of administration, achieve higher coverage by reducing vaccinee dropout between doses and allow for case-contact or ‘ring’ strategies to vaccinate the contacts of confirmed mpox patients.”
NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates, is reporting that the World Health Organization’s (“WHO”) preferred target product profile (“TPP”) aligns with the characteristics of its proprietary TNX-801 (horsepox, live virus) vaccine; Tonix is developing the vaccine for mpox (formerly known as monkeypox). WHO released the TPP at the Mpox Research and Innovation Scientific Conference, which was held Aug. 29–30, 2024,
According to the announcement, key elements of the WHO draft TPP include single-dose, durable protection, administration without special equipment and stability at ambient temperature.
“The characteristics of TNX-801 align with the draft TPP released at the WHO-sponsored Mpox Research and Innovation Scientific Conference,” said Tonix Pharmaceuticals CEO Seth Lederman, MD, in the press release. “The recent WHO declaration of a Public Health Emergency of International Concern (‘PHEIC’) underscores the urgent need for new vaccines to control this outbreak and save lives. We have been motivated to develop TNX-801 because single-dose vaccines simplify logistics of administration, achieve higher coverage by reducing vaccinee dropout between doses and allow for case-contact or ‘ring’ strategies to vaccinate the contacts of confirmed mpox patients.”
NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
